Axon Enterprise, Inc $AXON Shares Sold by Kingsbury Capital Investment Advisors LLC

Kingsbury Capital Investment Advisors LLC lessened its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 51.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,052 shares of the biotechnology company’s stock after selling 1,100 shares during the period. Kingsbury Capital Investment Advisors LLC’s holdings in Axon Enterprise were worth $590,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in AXON. Evergreen Capital Management LLC increased its holdings in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares in the last quarter. Synergy Financial Group LTD lifted its stake in shares of Axon Enterprise by 1.4% during the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock worth $996,000 after purchasing an additional 19 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Axon Enterprise by 1.2% in the second quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock worth $1,350,000 after buying an additional 19 shares during the period. Pure Financial Advisors LLC boosted its position in shares of Axon Enterprise by 6.7% in the fourth quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock worth $207,000 after buying an additional 23 shares during the period. Finally, Keel Point LLC grew its stake in shares of Axon Enterprise by 4.4% in the first quarter. Keel Point LLC now owns 599 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 25 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Piper Sandler raised their target price on Axon Enterprise from $724.00 to $732.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, July 22nd. Needham & Company LLC reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday. Citizens Jmp reissued a “market outperform” rating and set a $700.00 target price on shares of Axon Enterprise in a research report on Thursday, June 25th. Finally, Argus boosted their target price on shares of Axon Enterprise from $460.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $721.57.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $515.67 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $792.16. The business’s 50-day simple moving average is $569.47 and its 200 day simple moving average is $486.64. The stock has a market cap of $41.89 billion, a price-to-earnings ratio of 213.97, a price-to-earnings-growth ratio of 10.06 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The firm had revenue of $904.39 million during the quarter, compared to the consensus estimate of $876.42 million. During the same quarter in the prior year, the business posted $2.12 earnings per share. Axon Enterprise’s revenue for the quarter was up 35.3% on a year-over-year basis. As a group, sell-side analysts predict that Axon Enterprise, Inc will post 2.04 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 16,775 shares of Axon Enterprise stock in a transaction on Monday, August 31st. The shares were sold at an average price of $574.43, for a total value of $9,636,063.25. Following the completion of the sale, the president owned 296,974 shares in the company, valued at approximately $170,590,774.82. The trade was a 5.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey C. Kunins sold 9,605 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the completion of the sale, the insider directly owned 97,761 shares in the company, valued at $61,266,818.70. This represents a 8.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 56,380 shares of company stock valued at $32,582,366 in the last three months. Corporate insiders own 4.20% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.